Skip to main content
Clinical Trials/NCT05842629
NCT05842629
Recruiting
Not Applicable

Improved Diagnosis of Ovarian Cancer

University of Aarhus1 site in 1 country1,700 target enrollmentMay 15, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ovarian Neoplasms
Sponsor
University of Aarhus
Enrollment
1700
Locations
1
Primary Endpoint
Diagnostic efficiency of available imaging modalities by models and subjective evaluation for pre-operative diagnosis of adnexal masses
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and malignant adnexal masses in the hands of clinicians in Central Denmark Region.

Secondarily, we want to improve our management of adnexal masses by evaluating the complications and longitudinal changes in conservatively managed adnexal masses.

Data is registered prospectively but analyzed retrospectively.

Detailed Description

Imaging methods include ultrasonography (US) by varied observers, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computed Tomography (PET-CT). Imaging criteria are based on recommendations by the International Ovarian Tumor Analysis (IOTA) group. Educational efforts in IOTA terminology and systematic description at ultrasonography may support quality in the diagnostic process. Patients will be diagnosed and treated according to national and regional guidelines by the local clinicians. The project has been evaluated by the Ethical Committee in the Central Denmark Region prior to initiation. The aim of the power calculation for estimation of sample size is to be able to detect a difference in sensitivity from 75% to 90% at a threshold of 200 for Risk of Malignancy Index (RMI) and 10% for Assessment of Different NEoplasia of the adneXa (ADNEX) model and two-step-strategy / The Ovarian-Adnexal Reporting and Data System (O-RADS). To detect a difference in sensitivity (90% for ADNEX and two-step-strategy vs 75% for RMI at a specificity of 80%) at least 103 cases of malignancy should be included (calculated by using paired proportions).

Registry
clinicaltrials.gov
Start Date
May 15, 2021
End Date
December 2028
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ina Marie Dueholm Hjorth

Medical Doctor, PhD-student

Aarhus University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Diagnostic efficiency of available imaging modalities by models and subjective evaluation for pre-operative diagnosis of adnexal masses

Time Frame: 6 months

Accuracy measures for diagnosis of ovarian cancer: Sensitivity, specificity, positive and negative predictive values.

Area Under the Receiver Operating Characteristic Curve of ADNEX, O-RADS, two-step-strategy, Simple Rules and Risk of Malignancy Index.

Time Frame: 6 months

Comparison of AUC's between models/strategies

Secondary Outcomes

  • Observer variability(6 months)
  • Complications in women with conservatively managed adnexal masses(Up to 5 years)
  • Longitudinal changes in adnexal masses(Up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials